On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."    Read More

Recently I blogged about Merck advertising its cervical cancer vaccine Gardasil to a captive audience during trailers for the "Sex and the City" movie.    Read More

Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."    Read More

The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.    Read More

arr's Chairman and CEO Bruce Downey told me Teva's CEO Schlomo Yanai made the first move. But it didn't happen in a long-distance phone call from Tel Aviv to New Jersey. They say they were at an industry conference in Palm Beach outside some burger joint when the subject came up.    Read More

Symmetry Medical proves investors can speculate and play defense at the same time.   Read More

The researchers say the most vulnerable region to kidney stone outbreaks will probably be in the ever-hotter Southeast. "If, however, the risk suddenly climbs steeply at some threshold temperature, a band stretching from Kentucky to northern California would likely see the most new cases."    Read More

I am out in the field today shooting a story in Boston for the upcoming big Alzheimer's meeting the end of this month. But I wanted to pass along this nugget dug up by Pharmalot's Ed Silverman: The Pfizer Exec And The $300K Helicopter Bill.    Read More

More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.    Read More

After a knee-jerk reaction to the downside after the closing bell yesterday to the surprising four-cent miss by Genentech, the shares are rallying big time in the early regular trading session.    Read More